{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T20:09:47Z","timestamp":1788206987542,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T00:00:00Z","timestamp":1622764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011772","name":"Novartis Farmac\u00e9utica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011772","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IJC Heart & Vasculature"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.ijcha.2021.100821","type":"journal-article","created":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T13:52:52Z","timestamp":1623765172000},"page":"100821","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Effects and clinical implications of sacubitril\/valsartan on left ventricular reverse remodeling in patients affected by chronic heart failure: A 24-month follow-up"],"prefix":"10.1016","volume":"35","author":[{"given":"Carla","family":"Paolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Mugnai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Dalla Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Volpiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ferraglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Chiara","family":"Frigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Bilato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcha.2021.100821_b0005","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcha.2021.100821_b0010","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcha.2021.100821_b0015","first-page":"108","article-title":"Ejection fraction improvement and reverse remodeling achieved with Sacubitril\/Valsartan in heart failure with reduced ejection fraction patients","volume":"7","author":"Almufleh","year":"2017","journal-title":"Am. J. Cardiovasc. Dis."},{"key":"10.1016\/j.ijcha.2021.100821_b0020","article-title":"Impact of sacubitril\/valsartan on echo parameters in heart failure patients with reduced ejection fraction a prospective evaluation","volume":"25","author":"Bayard","year":"2019","journal-title":"Int. J. Cardiol. Heart Vasc."},{"key":"10.1016\/j.ijcha.2021.100821_b0025","first-page":"1","article-title":"Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial","author":"Desai","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.ijcha.2021.100821_b0030","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ijcha.2021.100821_b0035","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1161\/CIR.0b013e31829e8807","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ijcha.2021.100821_b0040","article-title":"Cause-specific death and risk factors of one-year mortality after implantable cardioverter-defibrillator implantation: a nationwide study","author":"Alhakak","year":"2020","journal-title":"Eur. Heart. J. Qual Care Clin. Outcomes"},{"key":"10.1016\/j.ijcha.2021.100821_b0045","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJM199906103402306","article-title":"The protective effects of estrogen on the cardiovascular system","volume":"340","author":"Mendelsohn","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcha.2021.100821_b0050","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1161\/hc1102.105267","article-title":"Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene","volume":"105","author":"Simoncini","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ijcha.2021.100821_b0055","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1161\/01.HYP.0000048702.55183.89","article-title":"Abolition of end-organ damage by antiandrogen treatment in female hypertensive transgenic rats","volume":"41","author":"Baltatu","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcha.2021.100821_b0060","doi-asserted-by":"crossref","first-page":"H2043","DOI":"10.1152\/ajpheart.01121.2005","article-title":"Testosterone enhances early cardiac remodeling after myocardial infarction, causing rupture and degrading cardiac function","volume":"290","author":"Cavasin","year":"2006","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.ijcha.2021.100821_b0065","doi-asserted-by":"crossref","first-page":"17464","DOI":"10.1074\/jbc.M414220200","article-title":"Nuclear factor-kappaB activation leads to down-regulation of fatty acid oxidation during cardiac hypertrophy","volume":"280","author":"Planavila","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijcha.2021.100821_b0070","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1152\/physiolgenomics.00265.2007","article-title":"Human cardiac-specific cDNA array for idiopathic dilated cardiomyopathy: sex-related differences","volume":"33","author":"Haddad","year":"2008","journal-title":"Physiol. Genomics"},{"key":"10.1016\/j.ijcha.2021.100821_b0075","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1136\/hrt.2008.164061","article-title":"Age and gender effects on the extent of myocardial involvement in acute myocarditis: a cardiovascular magnetic resonance study","volume":"95","author":"Cocker","year":"2009","journal-title":"Heart"},{"key":"10.1016\/j.ijcha.2021.100821_b0080","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10354-011-0892-8","article-title":"Sex and gender differences in myocardial hypertrophy and heart failure","volume":"161","author":"Regitz-Zagrosek","year":"2011","journal-title":"Wien. Med. Wochenschr."},{"key":"10.1016\/j.ijcha.2021.100821_b0085","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/eurjhf\/hfp108","article-title":"Both in- and out-hospital worsening of renal function predict outcome in patients with heart failure: results from the Coordinating Study Evaluating Outcome of Advising and Counseling in Heart Failure (COACH)","volume":"11","author":"Damman","year":"2009","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcha.2021.100821_b0090","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.cardfail.2007.04.008","article-title":"Worsening renal function and prognosis in heart failure: systematic review and meta-analysis","volume":"13","author":"Damman","year":"2007","journal-title":"J. Card Fail"},{"key":"10.1016\/j.ijcha.2021.100821_b0095","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1016\/j.jacc.2005.11.084","article-title":"Renal impairment and outcomes in heart failure: systematic review and meta-analysis","volume":"47","author":"Smith","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcha.2021.100821_b0100","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.jacc.2008.07.051","article-title":"Cardiorenal syndrome","volume":"52","author":"Ronco","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcha.2021.100821_b0105","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/ejhf.13","article-title":"Worsening renal function during renin-angiotensin-aldosterone system inhibitor initiation and long-term outcomes in patients with left ventricular systolic dysfunction","volume":"16","author":"Clark","year":"2014","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcha.2021.100821_b0110","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure","volume":"6","author":"Damman","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ijcha.2021.100821_b0115","doi-asserted-by":"crossref","first-page":"906","DOI":"10.3390\/jcm9040906","article-title":"Sacubitril\/valsartan induces global cardiac reverse remodeling in long-lasting heart failure with reduced ejection fraction: standard and advanced echocardiographic evidences","volume":"9","author":"Castrichini","year":"2020","journal-title":"J. Clin. Med."}],"container-title":["IJC Heart & Vasculature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906721001093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906721001093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T05:10:37Z","timestamp":1762492237000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352906721001093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":23,"alternative-id":["S2352906721001093"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcha.2021.100821","relation":{},"ISSN":["2352-9067"],"issn-type":[{"value":"2352-9067","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects and clinical implications of sacubitril\/valsartan on left ventricular reverse remodeling in patients affected by chronic heart failure: A 24-month follow-up","name":"articletitle","label":"Article Title"},{"value":"IJC Heart & Vasculature","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcha.2021.100821","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100821"}}